Ocular Surgery News
Many physicians are awaiting the results of a trial comparing two leading anti-VEGF agents in the treatment of neovascular age-related macular degeneration. But because study results will not be known for several years, they continue to practice with varying therapies, regimens and doses, trying to find an ideal treatment for their patients.